A Phase II Clinical Trial Examining the Impact Of Neoadjuvant Axitinib On Primary Tumor Response In Patients With Locally Advanced Clear Cell Renal Cell Carcinoma.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 15 Jan 2018
At a glance
- Drugs Axitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 09 Jan 2018 Planned primary completion date changed from 1 Feb 2019 to 1 Feb 2020.
- 10 Jul 2017 Results of post-hoc analysis published in the Urology
- 05 Jan 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Feb 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History